MedTrace Logo

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.

NCT00236795 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1494

Last updated 2011-06-08

No results posted yet for this study

Summary

The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.

Conditions

  • Contraception
  • Female Contraception

Interventions

DRUG

norelgestromin + ethinyl estradiol; triphasil.

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1997-01-31
Completion
1999-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00236795 on ClinicalTrials.gov